NASDAQ:APEN - Apollo Endosurgery Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $3.74 +0.01 (+0.27 %) (As of 05/19/2019 04:00 PM ET)Previous Close$3.74Today's Range$3.61 - $3.8352-Week Range$3.02 - $9.65Volume3,394 shsAverage Volume13,944 shsMarket Capitalization$81.98 millionP/E RatioN/ADividend YieldN/ABeta0.75 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. Its products include OverStitch and OverStitch Sx Endoscopic Suturing System that enables advanced endoscopic procedures by allowing physicians to place full thickness sutures and secure the approximation of tissue through a flexible endoscope; Orbera365 Managed Weight Loss System; and the BIB for the treatment of overweight and obese adults. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Brazil, Australia, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas. Receive APEN News and Ratings via Email Sign-up to receive the latest news and ratings for APEN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APEN Previous Symbol CUSIPN/A CIK1251769 Webwww.apolloendo.com Phone512-279-5100Debt Debt-to-Equity Ratio1.33 Current Ratio2.77 Quick Ratio2.24Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$60.85 million Price / Sales1.35 Cash FlowN/A Price / Cash FlowN/A Book Value$1.17 per share Price / Book3.20Profitability EPS (Most Recent Fiscal Year)($1.92) Net Income$-45,790,000.00 Net Margins-69.37% Return on Equity-97.89% Return on Assets-41.75%Miscellaneous Employees215 Outstanding Shares21,920,000Market Cap$81.98 million Next Earnings Date8/14/2019 (Estimated) OptionableNot Optionable Apollo Endosurgery (NASDAQ:APEN) Frequently Asked Questions What is Apollo Endosurgery's stock symbol? Apollo Endosurgery trades on the NASDAQ under the ticker symbol "APEN." How were Apollo Endosurgery's earnings last quarter? Apollo Endosurgery Inc (NASDAQ:APEN) issued its earnings results on Thursday, May, 2nd. The biotechnology company reported ($0.39) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.37) by $0.02. The biotechnology company earned $13.21 million during the quarter, compared to analyst estimates of $13.21 million. Apollo Endosurgery had a negative net margin of 69.37% and a negative return on equity of 97.89%. View Apollo Endosurgery's Earnings History. When is Apollo Endosurgery's next earnings date? Apollo Endosurgery is scheduled to release their next quarterly earnings announcement on Wednesday, August 14th 2019. View Earnings Estimates for Apollo Endosurgery. What price target have analysts set for APEN? 2 brokerages have issued twelve-month price targets for Apollo Endosurgery's stock. Their forecasts range from $3.00 to $4.00. On average, they expect Apollo Endosurgery's share price to reach $3.50 in the next twelve months. This suggests that the stock has a possible downside of 6.4%. View Analyst Price Targets for Apollo Endosurgery. What is the consensus analysts' recommendation for Apollo Endosurgery? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apollo Endosurgery in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Apollo Endosurgery. What are Wall Street analysts saying about Apollo Endosurgery stock? Here are some recent quotes from research analysts about Apollo Endosurgery stock: 1. According to Zacks Investment Research, "Apollo Endosurgery, Inc. is engaged in designing and manufacturing of medical devices for weight loss solutions and gastrointestinal disorders. The Company's product segment includes ORBERA (R), LAP-BAND (R) and OverStitch(TM). The ORBERA is an Intragastric Balloon System which is a weight loss aid for adults suffering from obesity. The LAP-BAND System is developed for weight reduction for patients with obesity. The OverStitch Endoscopic Suturing System enables endoscopic surgery. It operates primarily in Asia Pacific, European Office, Latin and South America and Costa Rica. Apollo Endosurgery, Inc., formerly known as Lpath, Inc., is headquatered in Austin, Texas. " (5/8/2019) 2. Northland Securities analysts commented, "We are upgrading Perform rating. Our PT remains the same. The stock is down a lot from our original downgrade, and we think it is prudent to move to the sidelines. Our core concerns about the story, though, remain. Key Points Our updated outlook is based on the following: Business outlook remains weak. The company has already pre-announced Q4 revenue range of ~$15M (+/- a few hundred thousand), which was lower than consensus of ~$16M." (1/2/2019) Has Apollo Endosurgery been receiving favorable news coverage? Headlines about APEN stock have trended somewhat positive this week, according to InfoTrie. The research group rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Apollo Endosurgery earned a coverage optimism score of 1.9 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term. Who are some of Apollo Endosurgery's key competitors? Some companies that are related to Apollo Endosurgery include Inovio Pharmaceuticals (INO), Utah Medical Products (UTMD), Westaim (WEDXF), Vapotherm (VAPO), SeaSpine (SPNE), Neuronetics (STIM), Pulse Biosciences (PLSE), Iradimed (IRMD), Cytosorbents (CTSO), Apyx Medical (APYX), Alphatec (ATEC), Liquidia Technologies (LQDA), Endologix (ELGX), T2 Biosystems (TTOO) and RenovaCare (RCAR). What other stocks do shareholders of Apollo Endosurgery own? Based on aggregate information from My MarketBeat watchlists, some companies that other Apollo Endosurgery investors own include Obalon Therapeutics (OBLN), Corbus Pharmaceuticals (CRBP), Second Sight Medical Products (EYES), Genocea Biosciences (GNCA), Arbutus Biopharma (ABUS), Anavex Life Sciences (AVXL), Nektar Therapeutics (NKTR), Novavax (NVAX), Progenics Pharmaceuticals (PGNX) and Sorrento Therapeutics (SRNE). Who are Apollo Endosurgery's key executives? Apollo Endosurgery's management team includes the folowing people: Mr. Todd Newton, CEO & Director (Age 56)Dr. Sergey Kantsevoy M.D., Co-Founder and Innovation PartnerMr. Anthony Kalloo M.D., Co-Founder and Innovation PartnerDr. Robert Hawes M.D., Co-Founder and Innovation PartnerDr. Peter Benjamin Cotton M.D., Co-Founder and Innovation Partner Who are Apollo Endosurgery's major shareholders? Apollo Endosurgery's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Gagnon Securities LLC (3.94%), NJ State Employees Deferred Compensation Plan (0.60%), Renaissance Technologies LLC (0.32%), Northern Trust Corp (0.12%) and Jacobs Levy Equity Management Inc. (0.08%). Company insiders that own Apollo Endosurgery stock include Bret Schwartzhoff, Holdings A/S Novo, Matthew S Crawford, Richard J Meelia, Sciences L P Ptv II, Stefanie L Cavanaugh, Stonepine Capital, LP and Todd Newton. View Institutional Ownership Trends for Apollo Endosurgery. Which major investors are selling Apollo Endosurgery stock? APEN stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp and Renaissance Technologies LLC. View Insider Buying and Selling for Apollo Endosurgery. Which major investors are buying Apollo Endosurgery stock? APEN stock was acquired by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., Gagnon Securities LLC and NJ State Employees Deferred Compensation Plan. Company insiders that have bought Apollo Endosurgery stock in the last two years include Bret Schwartzhoff, Matthew S Crawford, Richard J Meelia, Sciences L P Ptv II, Stefanie L Cavanaugh, Stonepine Capital, LP and Todd Newton. View Insider Buying and Selling for Apollo Endosurgery. How do I buy shares of Apollo Endosurgery? Shares of APEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Apollo Endosurgery's stock price today? One share of APEN stock can currently be purchased for approximately $3.74. How big of a company is Apollo Endosurgery? Apollo Endosurgery has a market capitalization of $81.98 million and generates $60.85 million in revenue each year. The biotechnology company earns $-45,790,000.00 in net income (profit) each year or ($1.92) on an earnings per share basis. Apollo Endosurgery employs 215 workers across the globe. What is Apollo Endosurgery's official website? The official website for Apollo Endosurgery is http://www.apolloendo.com. How can I contact Apollo Endosurgery? Apollo Endosurgery's mailing address is 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-279-5100 or via email at [email protected] MarketBeat Community Rating for Apollo Endosurgery (NASDAQ APEN)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 164 (Vote Outperform)Underperform Votes: 122 (Vote Underperform)Total Votes: 286MarketBeat's community ratings are surveys of what our community members think about Apollo Endosurgery and other stocks. Vote "Outperform" if you believe APEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APEN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/19/2019 by MarketBeat.com StaffFeatured Article: Different Options Trading Strategies Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.